Evaluate the Safety and Preliminary Efficacy of EXG110 in Subjects With Fabry Disease
Trial Parameters
Brief Summary
Objective: To explore the safety and tolerability of different doses of EXG110 with Fabre disease
Eligibility Criteria
Inclusion Criteria: 1. At the time of signing the informed consent, age ≥7, male or female 2. Clinical symptoms (at least one Fabry disease related symptom) and genetic diagnosis of Fabry disease, 3. Prior or no prior ERT treatment 4. Have renal or cardiac involvement (adults only) 5. All subjects of reproductive age voluntarily took effective contraception and prohibited sperm donation from entering the screening period until 52 weeks after dosing (main study period) 6. The subjects voluntarily participate and are fully informed, fully understand the research, can comply with the requirements of the research protocol, and are willing to complete the research as planned, and voluntarily provide biological samples for testing according to the requirements of the protocol Exclusion Criteria: 1. Screening period laboratory test results: a) aspartate aminotransferase or alanine aminotransferase \> 1.5× upper limit of normal (ULN);b) Total bilirubin \> 1.5× upper limit of normal (ULN);c) Al